ALZCHEM GROUP AG (ACT.DE) Stock Fundamental Analysis

FRA:ACT • DE000A2YNT30

147 EUR
+1 (+0.68%)
Last: Feb 16, 2026, 05:29 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

7

ACT gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 69 industry peers in the Chemicals industry. ACT scores excellent points on both the profitability and health parts. This is a solid base for a good stock. ACT has a decent growth rate and is not valued too expensively. With these ratings, ACT could be worth investigating further for quality investing!.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • ACT had positive earnings in the past year.
  • In the past year ACT had a positive cash flow from operations.
  • ACT had positive earnings in each of the past 5 years.
  • ACT had a positive operating cash flow in 4 of the past 5 years.
ACT.DE Yearly Net Income VS EBIT VS OCF VS FCFACT.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M 100M

1.2 Ratios

  • ACT's Return On Assets of 10.49% is amongst the best of the industry. ACT outperforms 94.20% of its industry peers.
  • ACT has a better Return On Equity (26.47%) than 95.65% of its industry peers.
  • With an excellent Return On Invested Capital value of 13.45%, ACT belongs to the best of the industry, outperforming 92.75% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for ACT is above the industry average of 7.09%.
  • The last Return On Invested Capital (13.45%) for ACT is above the 3 year average (12.06%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 10.49%
ROE 26.47%
ROIC 13.45%
ROA(3y)8.81%
ROA(5y)7.86%
ROE(3y)22.87%
ROE(5y)25.91%
ROIC(3y)12.06%
ROIC(5y)10.63%
ACT.DE Yearly ROA, ROE, ROICACT.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

  • With an excellent Profit Margin value of 10.97%, ACT belongs to the best of the industry, outperforming 84.06% of the companies in the same industry.
  • In the last couple of years the Profit Margin of ACT has grown nicely.
  • ACT has a better Operating Margin (15.93%) than 85.51% of its industry peers.
  • In the last couple of years the Operating Margin of ACT has grown nicely.
  • With an excellent Gross Margin value of 66.55%, ACT belongs to the best of the industry, outperforming 97.10% of the companies in the same industry.
  • ACT's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 15.93%
PM (TTM) 10.97%
GM 66.55%
OM growth 3Y17.53%
OM growth 5Y12.4%
PM growth 3Y14.29%
PM growth 5Y15.31%
GM growth 3Y2.01%
GM growth 5Y1.44%
ACT.DE Yearly Profit, Operating, Gross MarginsACT.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • ACT has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for ACT has been reduced compared to 1 year ago.
  • ACT has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ACT has been reduced compared to a year ago.
ACT.DE Yearly Shares OutstandingACT.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
ACT.DE Yearly Total Debt VS Total AssetsACT.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • ACT has an Altman-Z score of 4.89. This indicates that ACT is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of ACT (4.89) is better than 86.96% of its industry peers.
  • ACT has a debt to FCF ratio of 1.32. This is a very positive value and a sign of high solvency as it would only need 1.32 years to pay back of all of its debts.
  • ACT has a Debt to FCF ratio of 1.32. This is amongst the best in the industry. ACT outperforms 92.75% of its industry peers.
  • ACT has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.16, ACT is in the better half of the industry, outperforming 69.57% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 1.32
Altman-Z 4.89
ROIC/WACC1.85
WACC7.28%
ACT.DE Yearly LT Debt VS Equity VS FCFACT.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • ACT has a Current Ratio of 2.87. This indicates that ACT is financially healthy and has no problem in meeting its short term obligations.
  • ACT has a Current ratio of 2.87. This is amongst the best in the industry. ACT outperforms 81.16% of its industry peers.
  • A Quick Ratio of 1.77 indicates that ACT should not have too much problems paying its short term obligations.
  • The Quick ratio of ACT (1.77) is better than 81.16% of its industry peers.
Industry RankSector Rank
Current Ratio 2.87
Quick Ratio 1.77
ACT.DE Yearly Current Assets VS Current LiabilitesACT.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 24.12% over the past year.
  • ACT shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 24.60% yearly.
  • The Revenue has been growing slightly by 1.05% in the past year.
  • ACT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.06% yearly.
EPS 1Y (TTM)24.12%
EPS 3Y25.02%
EPS 5Y24.6%
EPS Q2Q%31.66%
Revenue 1Y (TTM)1.05%
Revenue growth 3Y9.49%
Revenue growth 5Y8.06%
Sales Q2Q%6.46%

3.2 Future

  • ACT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.26% yearly.
  • The Revenue is expected to grow by 6.02% on average over the next years.
EPS Next Y21.07%
EPS Next 2Y12.7%
EPS Next 3Y18.06%
EPS Next 5Y20.26%
Revenue Next Year2.51%
Revenue Next 2Y5.13%
Revenue Next 3Y8.61%
Revenue Next 5Y6.02%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ACT.DE Yearly Revenue VS EstimatesACT.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
ACT.DE Yearly EPS VS EstimatesACT.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 24.10, ACT is valued on the expensive side.
  • ACT's Price/Earnings is on the same level as the industry average.
  • When comparing the Price/Earnings ratio of ACT to the average of the S&P500 Index (26.68), we can say ACT is valued inline with the index average.
  • ACT is valuated rather expensively with a Price/Forward Earnings ratio of 22.72.
  • The rest of the industry has a similar Price/Forward Earnings ratio as ACT.
  • ACT is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 24.1
Fwd PE 22.72
ACT.DE Price Earnings VS Forward Price EarningsACT.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • ACT's Enterprise Value to EBITDA ratio is in line with the industry average.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ACT is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 42.77
EV/EBITDA 12.51
ACT.DE Per share dataACT.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

  • ACT's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • ACT has an outstanding profitability rating, which may justify a higher PE ratio.
  • ACT's earnings are expected to grow with 18.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.14
PEG (5Y)0.98
EPS Next 2Y12.7%
EPS Next 3Y18.06%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • ACT has a Yearly Dividend Yield of 1.25%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 2.15, ACT has a dividend in line with its industry peers.
  • Compared to the average S&P500 Dividend Yield of 1.84, ACT is paying slightly less dividend.
Industry RankSector Rank
Dividend Yield 1.25%

5.2 History

  • The dividend of ACT has a limited annual growth rate of 6.00%.
Dividend Growth(5Y)6%
Div Incr Years5
Div Non Decr Years5
ACT.DE Yearly Dividends per shareACT.DE Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 0.5 1 1.5

5.3 Sustainability

  • 49.16% of the earnings are spent on dividend by ACT. This is a bit on the high side, but may be sustainable.
  • The dividend of ACT is growing, but earnings are growing more, so the dividend growth is sustainable.
DP49.16%
EPS Next 2Y12.7%
EPS Next 3Y18.06%
ACT.DE Yearly Income VS Free CF VS DividendACT.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M
ACT.DE Dividend Payout.ACT.DE Dividend Payout, showing the Payout Ratio.ACT.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

ALZCHEM GROUP AG

FRA:ACT (2/16/2026, 5:29:51 PM)

147

+1 (+0.68%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)10-30
Earnings (Next)02-27
Inst Owners40.91%
Inst Owner ChangeN/A
Ins Owners28%
Ins Owner ChangeN/A
Market Cap1.50B
Revenue(TTM)563.86M
Net Income(TTM)61.84M
Analysts86
Price Target180.48 (22.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.25%
Yearly Dividend1.2
Dividend Growth(5Y)6%
DP49.16%
Div Incr Years5
Div Non Decr Years5
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.6%
PT rev (3m)11.74%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.34%
EPS NY rev (3m)2.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.31%
Valuation
Industry RankSector Rank
PE 24.1
Fwd PE 22.72
P/S 2.65
P/FCF 42.77
P/OCF 10.28
P/B 6.4
P/tB 6.5
EV/EBITDA 12.51
EPS(TTM)6.1
EY4.15%
EPS(NY)6.47
Fwd EY4.4%
FCF(TTM)3.44
FCFY2.34%
OCF(TTM)14.3
OCFY9.73%
SpS55.39
BVpS22.95
TBVpS22.6
PEG (NY)1.14
PEG (5Y)0.98
Graham Number56.13
Profitability
Industry RankSector Rank
ROA 10.49%
ROE 26.47%
ROCE 18.66%
ROIC 13.45%
ROICexc 16.12%
ROICexgc 16.26%
OM 15.93%
PM (TTM) 10.97%
GM 66.55%
FCFM 6.21%
ROA(3y)8.81%
ROA(5y)7.86%
ROE(3y)22.87%
ROE(5y)25.91%
ROIC(3y)12.06%
ROIC(5y)10.63%
ROICexc(3y)13.35%
ROICexc(5y)11.55%
ROICexgc(3y)13.5%
ROICexgc(5y)11.66%
ROCE(3y)16.73%
ROCE(5y)14.74%
ROICexgc growth 3Y25.57%
ROICexgc growth 5Y18.04%
ROICexc growth 3Y25.41%
ROICexc growth 5Y17.9%
OM growth 3Y17.53%
OM growth 5Y12.4%
PM growth 3Y14.29%
PM growth 5Y15.31%
GM growth 3Y2.01%
GM growth 5Y1.44%
F-Score6
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 1.32
Debt/EBITDA 0.33
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 125.34%
Profit Quality 56.58%
Current Ratio 2.87
Quick Ratio 1.77
Altman-Z 4.89
F-Score6
WACC7.28%
ROIC/WACC1.85
Cap/Depr(3y)118.98%
Cap/Depr(5y)119.68%
Cap/Sales(3y)5.65%
Cap/Sales(5y)6.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.12%
EPS 3Y25.02%
EPS 5Y24.6%
EPS Q2Q%31.66%
EPS Next Y21.07%
EPS Next 2Y12.7%
EPS Next 3Y18.06%
EPS Next 5Y20.26%
Revenue 1Y (TTM)1.05%
Revenue growth 3Y9.49%
Revenue growth 5Y8.06%
Sales Q2Q%6.46%
Revenue Next Year2.51%
Revenue Next 2Y5.13%
Revenue Next 3Y8.61%
Revenue Next 5Y6.02%
EBIT growth 1Y16.7%
EBIT growth 3Y28.68%
EBIT growth 5Y21.47%
EBIT Next Year50.25%
EBIT Next 3Y28.31%
EBIT Next 5Y19.11%
FCF growth 1Y37.23%
FCF growth 3Y62.42%
FCF growth 5Y94.14%
OCF growth 1Y166.77%
OCF growth 3Y34.7%
OCF growth 5Y19.23%

ALZCHEM GROUP AG / ACT.DE FAQ

Can you provide the ChartMill fundamental rating for ALZCHEM GROUP AG?

ChartMill assigns a fundamental rating of 7 / 10 to ACT.DE.


What is the valuation status for ACT stock?

ChartMill assigns a valuation rating of 4 / 10 to ALZCHEM GROUP AG (ACT.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for ALZCHEM GROUP AG?

ALZCHEM GROUP AG (ACT.DE) has a profitability rating of 9 / 10.


Can you provide the financial health for ACT stock?

The financial health rating of ALZCHEM GROUP AG (ACT.DE) is 9 / 10.


What is the earnings growth outlook for ALZCHEM GROUP AG?

The Earnings per Share (EPS) of ALZCHEM GROUP AG (ACT.DE) is expected to grow by 21.07% in the next year.